BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20588270)

  • 1. Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis.
    Xue A; Scarlett CJ; Chung L; Butturini G; Scarpa A; Gandy R; Wilson SR; Baxter RC; Smith RC
    Br J Cancer; 2010 Jul; 103(3):391-400. PubMed ID: 20588270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
    Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
    BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
    Capello M; Bantis LE; Scelo G; Zhao Y; Li P; Dhillon DS; Patel NJ; Kundnani DL; Wang H; Abbruzzese JL; Maitra A; Tempero MA; Brand R; Firpo MA; Mulvihill SJ; Katz MH; Brennan P; Feng Z; Taguchi A; Hanash SM
    J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
    Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
    World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
    Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
    Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers.
    Kim J; Bamlet WR; Oberg AL; Chaffee KG; Donahue G; Cao XJ; Chari S; Garcia BA; Petersen GM; Zaret KS
    Sci Transl Med; 2017 Jul; 9(398):. PubMed ID: 28701476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
    Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
    Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer.
    Chung L; Moore K; Phillips L; Boyle FM; Marsh DJ; Baxter RC
    Breast Cancer Res; 2014 Jun; 16(3):R63. PubMed ID: 24935269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
    Yoneyama T; Ohtsuki S; Honda K; Kobayashi M; Iwasaki M; Uchida Y; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Huang W; Yamada T; Tachikawa M; Terasaki T
    PLoS One; 2016; 11(8):e0161009. PubMed ID: 27579675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma.
    Lin C; Wu WC; Zhao GC; Wang DS; Lou WH; Jin DY
    Medicine (Baltimore); 2016 Aug; 95(31):e4527. PubMed ID: 27495108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer.
    Jahan R; Ganguly K; Smith LM; Atri P; Carmicheal J; Sheinin Y; Rachagani S; Natarajan G; Brand RE; Macha MA; Grandgenett PM; Kaur S; Batra SK
    EBioMedicine; 2019 Apr; 42():375-385. PubMed ID: 30956167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma.
    Xu P; Wang X; Qian J; Li Z; Yao J; Xu A
    Medicine (Baltimore); 2021 Feb; 100(6):e24651. PubMed ID: 33578593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
    Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
    World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic classification of pancreatic adenocarcinoma tissue using protein chip technology.
    Scarlett CJ; Smith RC; Saxby A; Nielsen A; Samra JS; Wilson SR; Baxter RC
    Gastroenterology; 2006 May; 130(6):1670-8. PubMed ID: 16697731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9.
    Majumder S; Taylor WR; Foote PH; Berger CK; Wu CW; Mahoney DW; Bamlet WR; Burger KN; Postier N; de la Fuente J; Doering KA; Lidgard GP; Allawi HT; Petersen GM; Chari ST; Ahlquist DA; Kisiel JB
    Clin Cancer Res; 2021 May; 27(9):2523-2532. PubMed ID: 33593879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A migration signature and plasma biomarker panel for pancreatic adenocarcinoma.
    Balasenthil S; Chen N; Lott ST; Chen J; Carter J; Grizzle WE; Frazier ML; Sen S; Killary AM
    Cancer Prev Res (Phila); 2011 Jan; 4(1):137-49. PubMed ID: 21071578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline.
    Liu X; Zheng W; Wang W; Shen H; Liu L; Lou W; Wang X; Yang P
    Br J Cancer; 2017 Dec; 117(12):1846-1854. PubMed ID: 29123261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.
    Staal B; Liu Y; Barnett D; Hsueh P; He Z; Gao C; Partyka K; Hurd MW; Singhi AD; Drake RR; Huang Y; Maitra A; Brand RE; Haab BB
    Clin Cancer Res; 2019 May; 25(9):2745-2754. PubMed ID: 30617132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of diagnostic biomarkers for pancreatic cancer in immunodepleted serum by SELDI-TOF MS.
    Xue A; Gandy RC; Chung L; Baxter RC; Smith RC
    Pancreatology; 2012; 12(2):124-9. PubMed ID: 22487522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
    Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J
    World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.